UPDATE -- Longeveron Provides Corporate Update and

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – ...

Related Keywords

Miami ,Florida ,United States ,Nagoya ,Aichi ,Japan , ,National Center ,Company Phase ,Drug Administration ,Nasdaq ,Longeveron Inc ,Exchange Commission ,Stern Ir Inc ,Juntendo University Hospital Tokyo ,Longeveron Or Company ,Aging Related Frailty ,Chris Min ,Interim Chief Executive Officer ,Chief Medical ,Related Frailty ,Anticipated Milestones ,Left Heart Syndrome ,Fast Track ,Rare Pediatric Disease ,Orphan Drug Designations ,Juntendo University Hospital ,United States Food ,Hypoplastic Left Heart Syndrome ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Lgvn ,Longeveron ,